INTRODUCTION AND OBJECTIVES: Persistent prostatic specific antigen (PSA) represents a poor prognostic factor for recurrence after radical prostatectomy (RP). To investigate the impact of persistent PSA after RP on long-term oncologic outcomes and to assess patient characteristics associated with persistent PSA.
METHODS: Within a high-volume center database we identified patients who harbored persistent (!0.1ng/ml) vs. undetectable PSA (<0.1ng/ml) at six weeks after RP. Patients with neo-and/or adjuvant androgen deprivation therapy were excluded. Logistic regression models tested for prediction of persistent PSA. Kaplan-Meier analyses and Cox regression models tested the effect of persistent PSA on metastasis-free (MFS), overall survival (OS) and cancer-specific survival (CSS) rates. Propensity score matching was performed to test the impact of salvage radiotherapy (SRT) on OS and CSS in patients with persistent PSA.
RESULTS CONCLUSIONS: Persistent PSA is associated with worse oncologic outcome after RP, namely metastasis, death and cancerspecific death. In patients with persistent PSA, SRT resulted in improved OS and CSS. SRT may result in a survival benefit in well selected patients.
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MP66-15 PREDICTING FACTORS FOR PROGRESSION TO CASTRATION-RESISTANT PROSTATE CANCER AFTER BIOCHEMICAL RECURRENCE IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER WHO UNDERWENT RADICAL PROSTATECTOMY
Takeshi Hashimoto*, Jun Nakashima, Yutaka Nakata, Yuki Hirasawa, Naohiro Kamoda, Yosuke Hirasawa, Naoya Satake, Tatsuo Gondo, Yoshio Nakagami, Kazunori Namiki, Yoshio Ohno, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Approximately 30% of men who undergo radical prostatectomy (RP) experience biochemical recurrence (BCR) within 5 years. However, since androgen deprivation therapy (ADT) or salvage radiation therapy might be effective for a long time after BCR, BCR is not the surrogate for cancer-specific mortality in patients with prostate cancer after surgery. Previous reports have suggested that a considerable number of patients will die from prostate cancer within almost 3 years once prostate cancer develops to castration-resistant prostate cancer (CRPC). Therefore, progression to CRPC can be a powerful surrogate for the prediction of prostate cancer mortality. The aim of the present study was to determine prognostic factors associated with progression to CRPC.
METHODS: Between 2000 and 2016, 2,210 patients underwent RP at our institution. Univariate and multivariate Cox proportional hazards models were used to identify clinical covariates that were significantly associated with progression to CRCP. RESULTS: Of 402 patients who experienced BCR, prostate cancer in 34 patients progressed to CRCP during the study period. In univariate analyses, time to BCR from surgery, initial prostate-specific antigen level, pathological tumor stage, positive surgical margins, and the presence of lymph node involvement were not significantly associated with progression to CRCP. However, the pathological Gleason score and presence of lymphovascular invasion (LVI) were significantly associated with progression to CRCP. In multivariate analysis, both the pathological Gleason score ( 7 vs. !8; hazard ratio [HR] [2.23, p[0.005) and LVI (positive vs. negative; HR[3.87, p[0.003) were independent predictors for progression to CRCP after BCR. We established a risk stratification model using the independent factors. In the high-risk group, the 10-year progression to CRPC-free survival rate was 65.6%, which was significantly lower than 87.0% and 95.7% in the intermediate and low-risk groups, respectively (Figure 1) .
CONCLUSIONS: The present study suggested that the risk of progression to CRPC after BCR was higher in patients with high Gleason scores and/or the presence of LVI in prostatectomy specimens. The aim of this study was to evaluate predictors of residual tumor and clinical prognosis in T1a-T1b (incidental) prostate cancer by analysis of specimens from men undergoing surgery for benign prostatic hyperplasia.
METHODS: We retrospectively reviewed medical records of incidental prostate cancer patients who had undergone radical prostatectomy. Patients whose tumor statuses were further confirmed by prostate biopsy, or who had used androgen deprivation therapy before radical prostatectomy, were excluded. Clinical and pathological parameters were analyzed to evaluate residual tumor and clinical prognosis. We used univariate and multivariate logistic regression analyses, as well as receiver operator characteristics, to predict residual tumor (pT0).
